In Vitro Verification of Antithrombotic Effect of Recombinant Soluble Nucleotide Triphosphate Diphosphohydrolase 1

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 4, 2004, Pages 379-384

  Sampram, Ellis S K ^a   Ouriel, Kenneth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; APYRASE; CD39 ANTIGEN; FIBRINOGEN; HEPARIN; POLITEF; RECOMBINANT SOLUBLE NUCLEOTIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD VESSEL INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRADATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBRIN DEPOSITION; HUMAN; PERFUSION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOGENESIS;

EID: 1842505718     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000121409.46920.B8     Document Type: Article

References (27)

1. Cho JS, Ouriel K, DeWeese JA, Green RM, Chen GY, Stoughton J. Thrombus formation on polytetrafluoroethylene surfaces: the importance of von Willebrand factor. Cardiovascular Surg 1995; 3:645-651.
2. Rhee RY, Donayre CE, Ouriel K, Neschis DG, Shortell CK. Low dose heparin therapy: in vitro verification of antithrombotic effect. J Vasc Surg 1991; 14:628-534.
3. Birk AV, Broekman MJ, Gladek EM, et al. Role of extracellular ATP metabolism in regulation of platelet reactivity. J Lab Med 2002; 140:166-75.
4. Gayle RB III, Maliszewski CR, Gimpel SD, et al. Inhibition of platelet Function by recombinant soluble ecto-ADPase/CD39. J Clin Invest 1998; 101: 1851-1859.
5. Plesner L. Ecto-ATPase: identities and functions. Int Rev Cytol 1995; 158: 141-214.
6. Wang T-F, Guidotti G. CD39 is an ecto- (Ca2+, Mg2+)-apyrase. J Biol Chem 1996; 271:9898-9901.
7. Kaczmarek E, Koziak K, Sevigny J, et al. Identification and characterization of CD39 vascular ATP diphosphohydrolase. J Biol Chem 1996; 271:33116-33122.
8. Di Virgilio, Chiozzi P, Ferrari D, et al. Nucleotide receptors: an emerging family of regulatory molecules in the blood cells. Blood 2001; 97:587-600.
9. Enjyoji K, Sevigny J, Lin Y, et al. Targeted disruption of cd39/ATPdiphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999; 5:1010-1017.
10. Christoforidis S, Papamarcaki T, Galaris D, Kellner R, Tsolas O. Purification and properties of human placental ATP diphosphohydrolase. Eur J Biochem 1995; 234:66-74.
11. Marcus AJ, Safir LB, Hajjar KA, et al. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase: thromboregulation by endothelial cells. J Clin Invest 1991; 88:1690-1696.
12. Cote YP, Filep JG, Battistini B, Gauvreau j, Sirois p, Beaudoin AR. Characterization of ATP-diphosphohydrolase activities in the intima and media of the bovine aorta: evidence for a regulatory role in platelet activation in vitro. Biochem Biophys Acta 1992; 1139:133-142.
13. Marcus AJ, Broekman MJ, Drosopoulos JHF, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99:1351-1360.
14. Luthje J. Origin, metabolism and function of extracellular adenine nucleotides in the blood. Klin Wochenschr 1989; 67:317-327.
15. Kansas GS, Wood GS, Tedder TF. Expression, distribution, and biochemistry of human CD39: role in activation-associated homotypic adhesion of lymphocytes. J Immunol 1991; 146: 2235-2244.
16. Sevigny J, Robson SC, Waelkens E, Csizmadia E, Smith RN, Lemmens R. Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase. J Biol Chem 2000; 275: 5640-5647.
17. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J 1993; 7:516-522.
18. Kaneider NC, Egger P, Dunzendorfer S, et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in enthothelial cells by HMG-CoA reductase inhibition: effects of Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 2002; 22: 894-900.
19. Sevigny J, Sundberg C, Braun N, et al. Differential catalytic properties and vascular topography of murine nucleoside triphophate diphosphohydrolase 1 (NTPDase 1) and NTPDase 2 have implications for thromboregulation. Blood 2002; 99:2801-2809.
20. Scazziota A, Altman R, Rouvier J et al. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATPase release, and P-selectin expression. Thromb Res 2000; 100:479-88.
21. Pinsky DJ, Broekman MJ, Peschon JJ, et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002; 109: 1031-1040.
22. Burns P, Lima E, Bradbury AW. What constitutes best medical therapy for peripheral arterial disease? Eur J Vasc Endovasc Surg 2002; 24:6-12.
23. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348:1329-39.
24. Jauhar R, Bergman G, Savino S, et al. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting. Am J Cardiol 1999; 84: 726-728.
25. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 304:81-106.
26. Birk AV, Bubman D, Broekman MJ, et al. Role of a novel soluble nucleotide phospho-hydrolase from sheep plasma in inhibition of platelet reactivity: hemostasis, thrombosis, and vascular biology. J Lab Med 2002; 139:116-24.
27. Marcus AJ, Broekman MJ, Drosopoulos JH, Pinsky DJ, Islam N, Maliszewsk CR. Inhibition of platelet by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases. Ital Heart J 2001; 2:824-30.